Navigation Links
ImQuest Presents Data on the Anti-Hepatitis B Virus Activity of Pyrimidinediones at the 13th ISVHLD Meeting in Washington D.C.
Date:3/31/2009

FREDERICK, Md., March 31 /PRNewswire/ -- ImQuest Life Sciences today presented important new results on the continued development of the pyrimidinedione small molecules as antiviral agents at the 13th International Symposium on Viral Hepatitis and Liver Disease meeting held last week in Washington D.C. ImQuest's screening efforts have identified ten pyrimidinediones as inhibitors of HBV replication, with two compounds yielding potent inhibition of HBV replication at sub-micromolar concentration levels. The two lead molecules, IQP-0568 and IQP-0589 have also been shown to be active non-nucleoside inhibitors of HIV replication, but inactive against a panel of other RNA and DNA viruses, suggesting specificity for antiviral activity against viruses that encode a reverse transcriptase. These studies provide a fundamental structural basis for the development of first in class non-nucleoside inhibitors of HBV replication. The data were presented by Todd B. Parsley, Ph.D., Director of Hepatitis Virus Research as a component of a session entitled, "Experimental Approaches to Therapy of HBV." The studies included ImQuest co-authors Lu Yang, MD and Robert W. Buckheit, Jr., Ph.D.

"These results reveal the potential for the development of the pyrimidinediones as a first in class non-nucleoside inhibitor of HBV infection," said Dr. Buckheit, Executive Vice President and Chief Scientific Officer of ImQuest Life Sciences. "These studies are also intriguing from the perspective of potential treatment options for patients co-infected with HBV and HIV."

The research presented continues the scientific partnership between ImQuest Life Sciences and Samjin Pharmaceuticals as a component of their joint efforts to develop new and novel anti-infective and anti-cancer therapeutics.

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in early stage drug development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective therapeutic and microbicide development services to the biotechnology and pharmaceutical industry.

    For further information regarding this press release please contact:

    Robert W. Buckheit, Jr., Ph.D.
    Executive Vice President and Chief Scientific Officer
    ImQuest Life Sciences, Inc.
    301-696-0274
    rbuckheit@imquest.com


'/>"/>
SOURCE ImQuest Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs
2. ImQuest Presents IND-Enabling Safety Pharmacology and Pharmacokinetic Data for the Therapeutic HIV Compound IQP-0410 at Conference on Retroviruses and Opportunistic Infections
3. ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission
4. ImQuest Awarded SBIR Grant to Define the Mechanism of Action of Their Lead Anti-HIV Therapeutic Compound IQP-0410
5. Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
6. EPA Presents Initial Results from Caliper Life Sciences ToxCast Screening Effort
7. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
8. Agendia Presents Data Supporting MammaPrints Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference
9. Commonwealth Biotechnologies Presents Data at Forensic Sciences Meeting Confirming Benefits of ZyGEMs DNA Extraction Technology
10. Prous Institute Presents Innovative Approach to Drug Discovery
11. PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... representations of a complex biological network, a depiction of a system of linkages ... said Dmitry Korkin, PhD, associate professor of computer science at Worcester Polytechnic Institute ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global contract research, ... improve patient outcomes and quality of life, will now be offering its impurity ... to new regulatory requirements for all new drug products, including the finalization of ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... compared the implantation and pregnancy rates in frozen and fresh in vitro ... of progesterone and maternal age to IVF success. , After comparing the results ...
Breaking Biology Technology:
(Date:4/18/2017)...  Socionext Inc., a global expert in SoC-based imaging and computing ... M820, which features the company,s hybrid codec technology. A demonstration utilizing ... Inc., will be showcased during the upcoming Medtec Japan at Tokyo ... Las Vegas Convention Center April 24-27. ... Click here for an image ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
Breaking Biology News(10 mins):